Matthew Salomon is a product strategist at Sleuth Insights, where he covers oncology and immunology and inflammation (I&I). He writes Sleuth's quarterly intelligence reports on ADCs, I&I, radiopharmaceuticals and RNA-based therapies, along with competitive landscapes on KRAS and pan-RAS, AML and PD-(L)1 x VEGF bispecifics, and he delivers Sleuth Concierge engagements for clients. Before Sleuth he was at ClearView Healthcare Partners, a life sciences strategy consultancy, where he specialized in M&A work for biopharma and private equity buyers, as well as pricing and market access. He holds an Sc.B. in neuroscience from Brown University.
